Clinical Trials - February 1, 2018
Novo Nordisk demonstrate positive results with Semaglutide
The results from the SUSTAIN 7 trial, investigating the efficacy and safety of 0.5 mg semaglutide compared with 0.75 mg dulaglutide and 1.0 mg semaglutide compared with 1.5 mg dulaglutide, when added to metformin, have been published in The Lancet Diabetes & Endocrinology. The 40-week trial showed that people with type 2 diabetes treated with once-weekly […]
Pharma Business - January 31, 2018
Novo Nordisk does not intend to make a revised proposal for Ablynx
The company notes the announcement of Sanofi’s agreed acquisition of Ablynx and confirms that it will not be making a revised proposal. On 8 January, Novo Nordisk announced its proposal to acquire Ablynx for up to EUR 30.50 per share in cash, consisting of EUR 28.00 upfront and EUR 2.50 in Contingent Value Rights. Novo Nordisk […]
Global report - January 29, 2018
Sanofi acquires Ablynx for 3.9 billion EUR
Sanofi will acquire the Belgian biotech company Ablynx for 3.9 billion euros ($4.8 billion), just a few days after the company turned down Novo Nordisk’s bid. The acquisition is Sanofi’s second major takeover deal this month following its acquisition of Bioverativ. “Since our founding in 2001, our team has been focused on unlocking the power of […]
Pharma Business - January 25, 2018
Ablynx rejects Novo Nordisk’s $3.1 billion bid
The Danish pharma giant’s proposal to acquire the Belgian biotech group Ablynx for EUR 28.00 per share in cash has been turned down. This proposal is the second proposal that Novo Nordisk has made to Ablynx’s Board of Directors and represents up to approximately a 14% increase over the first proposal. Ablynx has thus so […]
Pharma Business - September 11, 2017
Novo Nordisk announces conclusion of investigation of marketing practices
Novo Nordisk has reached a resolution with the US federal government and the states about an investigation launched in February 2011 concerning sales and marketing practices for Victoza, a medicine to treat type 2 diabetes. The investigation was disclosed by Novo Nordisk for the first time in a company announcement on 16 February 2011. The […]
Pharma Business - August 11, 2017
Novo’s Victoza has been approved in the EU
The European Commission has approved an update to the Victoza (liraglutide) EU label that expands the indication to reflect both improving blood sugar and cardiovascular (CV) events as integral parts of type 2 diabetes treatment. Victoza is the only GLP-1 that is proven to prevent CV events in people with type 2 diabetes and high […]
